The global breast ultrasound market size accounted for USD 2.30 billion in 2024, grew to USD 2.62 billion in 2025 and is expected to be worth around USD 8.67 billion by 2034, registering a healthy CAGR of 14.21% between 2024 and 2034. The North America breast ultrasound market size is evaluated at USD 0.83 billion in 2024 and is expected to grow at a CAGR of 14.24% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Breast Ultrasound Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Breast Ultrasound Market, by Product, 2024-2034
8.1.1. Conventional Breast Ultrasound (CBUS)
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Automated Breast Ultrasound (ABUS)
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Breast Ultrasound Market, by End Use, 2024-2034
9.1.1. Hospital
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Diagnostics Imaging Laboratories
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2021-2034)
10.1.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End Use (2021-2034)
11.1. GE HealthCare.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Koninklijke Philips N.V.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Siemens Healthineers AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CANON MEDICAL SYSTEMS CORPORATION
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Telemed Medical Systems Srl
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hologic, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. FUKUDA DENSHI
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Supersonic Imagine
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Lunit Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Delphinus Medical Technologies, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample